Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. (Q34099716)

31 July 2017

1 reference

title

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. (English)

1 reference

single-nucleotide polymorphism

31 July 2017

main subject

1 reference

1 reference

1 reference

Christine E Staatz

0 references

Lucy K Goodman

0 references

Susan E Tett

1 reference

31 July 2017

publication date

1 March 2010

1 reference

Clinical Pharmacokinetics

31 July 2017

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

141-175

1 reference

The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients

31 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11317350-000000000-00000

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

21 January 2018

1 reference

12 December 2020

The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients

1 reference

12 December 2020

Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients

1 reference

12 December 2020

Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?

1 reference

12 December 2020

Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine

1 reference

12 December 2020

The genetic determinants of the CYP3A5 polymorphism

1 reference

12 December 2020

Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?

1 reference

12 December 2020

Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients

1 reference

12 December 2020

Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene

1 reference

12 December 2020

Increased transcriptional activity of the CYP3A4*1B promoter variant

1 reference

12 December 2020

Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients

1 reference

12 December 2020

The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients

1 reference

12 December 2020

Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors

1 reference

12 December 2020

P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice

1 reference

12 December 2020

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

1 reference

12 December 2020

Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism

1 reference

12 December 2020

Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations

1 reference

12 December 2020

The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function

1 reference

12 December 2020

Genetic contribution to variable human CYP3A-mediated metabolism

1 reference

12 December 2020

Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.

1 reference

12 December 2020

Expression of CYP3A in the Human Liver — Evidence that the Shift between CYP3A7 and CYP3A4 Occurs Immediately After Birth

1 reference

12 December 2020

Expression of cytochrome P450 3A in amphibian, rat, and human kidney

1 reference

12 December 2020

Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients

1 reference

12 December 2020

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation

1 reference

12 December 2020

C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation

1 reference

12 December 2020

CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam

1 reference

12 December 2020

Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

1 reference

12 December 2020

Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients1

1 reference

12 December 2020

Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects

1 reference

12 December 2020

No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients

1 reference

12 December 2020

Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians

1 reference

12 December 2020

Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids

1 reference

12 December 2020

Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects

1 reference

12 December 2020

The ontogeny of drug metabolism enzymes and implications for adverse drug events

1 reference

12 December 2020

Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients

1 reference

12 December 2020

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism

1 reference

12 December 2020

Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients

1 reference

12 December 2020

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update

1 reference

12 December 2020

Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.

1 reference

12 December 2020

Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects

1 reference

12 December 2020

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

1 reference

12 December 2020

MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients.

1 reference

12 December 2020

CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

1 reference

12 December 2020

Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

1 reference

12 December 2020

Pharmacogenetics in solid organ transplantation: current status and future directions

1 reference

12 December 2020

Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat

1 reference

12 December 2020

CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients

1 reference

12 December 2020

An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients

1 reference

12 December 2020

Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

1 reference

12 December 2020

CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus

1 reference

12 December 2020

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus

1 reference

12 December 2020

MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells

1 reference

12 December 2020

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients

1 reference

12 December 2020

Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms

1 reference

12 December 2020

CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation

1 reference

12 December 2020

Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism

1 reference

12 December 2020

Role of pharmacogenetics of immunosuppressive drugs in organ transplantation.

1 reference

12 December 2020

Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro

1 reference

12 December 2020

Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients

1 reference

12 December 2020

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

1 reference

12 December 2020

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine

1 reference

12 December 2020

Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation

1 reference

12 December 2020

Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients

1 reference

12 December 2020

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

1 reference

12 December 2020

Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

1 reference

12 December 2020

CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study

1 reference

12 December 2020

In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model

1 reference

12 December 2020

Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1).

1 reference

12 December 2020

Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans

1 reference

12 December 2020

In vitro metabolism of cyclosporine A by human kidney CYP3A5.

1 reference

12 December 2020

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

1 reference

12 December 2020

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

12 December 2020

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

12 December 2020

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

12 December 2020

CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects.

1 reference

12 December 2020

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

1 reference

12 December 2020

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation

1 reference

12 December 2020

MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

1 reference

12 December 2020

RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

1 reference

12 December 2020

Identification of functionally variant MDR1 alleles among European Americans and African Americans

1 reference

12 December 2020

Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.

1 reference

12 December 2020

Developmental expression of the major human hepatic CYP3A enzymes

1 reference

12 December 2020

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations

1 reference

12 December 2020

1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation

1 reference

12 December 2020

A "silent" polymorphism in the MDR1 gene changes substrate specificity

1 reference

12 December 2020

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

1 reference

12 December 2020

Therapeutic monitoring of calcineurin inhibitors for the nephrologist

1 reference

12 December 2020

Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4

1 reference

12 December 2020

Alternative cyclosporine metabolic pathways and toxicity

1 reference

12 December 2020

CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients

1 reference

12 December 2020

Does inhibition of P-glycoprotein lead to drug-drug interactions?

1 reference

12 December 2020

Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene

1 reference

12 December 2020

Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics

1 reference

12 December 2020

Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability

1 reference

12 December 2020

Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

1 reference

12 December 2020

Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients

1 reference

12 December 2020

Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients

1 reference

12 December 2020

Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients

1 reference

12 December 2020

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation

1 reference

12 December 2020

Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics

1 reference

12 December 2020

CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele

1 reference

12 December 2020

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

1 reference

12 December 2020

Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation

1 reference

12 December 2020

Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients

1 reference

12 December 2020

The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells

1 reference

12 December 2020

The drug efflux-metabolism alliance: biochemical aspects.

1 reference

12 December 2020

Significance of the minor cytochrome P450 3A isoforms.

1 reference

12 December 2020

MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients.

1 reference

12 December 2020

Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region

1 reference

12 December 2020

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

1 reference

12 December 2020

Importance of P-glycoprotein for drug disposition in humans

1 reference

12 December 2020

Cyclosporin metabolism in transplant patients

1 reference

12 December 2020

Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation

1 reference

12 December 2020

Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients

1 reference

12 December 2020

The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.

1 reference

12 December 2020

Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance

1 reference

12 December 2020

MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects

1 reference

12 December 2020

Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients

1 reference

12 December 2020

The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer

1 reference

12 December 2020

Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients

1 reference

12 December 2020

Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

1 reference

12 December 2020

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

1 reference

12 December 2020

Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects

1 reference

12 December 2020

Pharmacogenetics of immunosuppressants: progress, pitfalls and promises

1 reference

12 December 2020

Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms

1 reference

12 December 2020

Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects

1 reference

12 December 2020

CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.

1 reference

12 December 2020

The superfamily of organic anion transporting polypeptides

1 reference

12 December 2020

CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients

1 reference

12 December 2020

Pharmacogenomics--drug disposition, drug targets, and side effects

1 reference

12 December 2020

Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus

1 reference

12 December 2020

Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1).

1 reference

12 December 2020

Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements

1 reference

12 December 2020

MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients.

1 reference

12 December 2020

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

1 reference

12 December 2020

Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions

1 reference

12 December 2020

Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine

1 reference

12 December 2020

10.2165/11317350-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1037737386

0 references

1 reference